Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Purchases 150,000 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 150,000 shares of the stock in a transaction dated Friday, March 28th. The shares were bought at an average cost of $1.70 per share, for a total transaction of $255,000.00. Following the acquisition, the chief executive officer now owns 213,651,448 shares in the company, valued at $363,207,461.60. The trade was a 0.07 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Monday, March 17th, Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.74 per share, with a total value of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost acquired 67,434 shares of OPKO Health stock. The stock was purchased at an average price of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost bought 47,537 shares of OPKO Health stock. The stock was purchased at an average price of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.48 per share, for a total transaction of $740,000.00.

OPKO Health Trading Down 2.3 %

OPKO Health stock opened at $1.70 on Friday. OPKO Health, Inc. has a 12 month low of $1.15 and a 12 month high of $2.04. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -8.95 and a beta of 1.70. The business has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $1.58. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million during the quarter, compared to analyst estimates of $155.42 million. As a group, equities analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC raised its position in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 12,417 shares during the period. Orion Portfolio Solutions LLC acquired a new position in shares of OPKO Health in the 3rd quarter worth approximately $45,000. Cibc World Markets Corp bought a new position in shares of OPKO Health during the 4th quarter worth approximately $45,000. Finally, Zacks Investment Management acquired a new stake in OPKO Health in the 4th quarter valued at $49,000. 64.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on OPK. Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, March 19th. Finally, StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.